---
title: "4D Molecular Therapeutics reports positive 2-year PRISM Phase 2b data, 78–87% reduction in injections"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293214961.md"
description: "4D Molecular Therapeutics reported positive 2-year PRISM Phase 2b data for 4D-150, demonstrating durable vision maintenance and significant treatment burden reductions. The overall cohort saw a 78% reduction in supplemental injections compared to aflibercept, with recently diagnosed patients achieving an 87% reduction. Safety profiles were favorable, with no new serious ocular events observed."
datetime: "2026-07-20T12:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293214961.md)
  - [en](https://longbridge.com/en/news/293214961.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293214961.md)
generator: "portal-rs"
---

# 4D Molecular Therapeutics reports positive 2-year PRISM Phase 2b data, 78–87% reduction in injections

**4D Molecular Therapeutics reported positive 2-year PRISM Phase 2b results showing durable vision maintenance and large reductions in treatment burden with 4D-150.**

**Key Highlights:**

-   Phase 2b (n=45) showed consistent BCVA maintenance and CST control through 2 years for single intravitreal 4D-150 dosing.
-   Overall cohort had 78% treatment-burden reduction (2.7 mean supplemental injections vs. 12.0 projected with on-label aflibercept).
-   Recently diagnosed subgroup (≤6 months) had 87% reduction (1.6 mean supplemental injections vs. 12.0 projected).
-   Safety for Phase 3 dose (n=71 combined): well tolerated with 2.8% transient mild IOI within ~28 weeks; no new inflammation or serious ocular events through data cutoff.

Original SEC Filing: 4D Molecular Therapeutics, Inc. \[ FDMT \] - 8-K - Jul. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FDMT.US](https://longbridge.com/en/quote/FDMT.US.md)

## Related News & Research

- [4D Molecular Therapeutics CEO David Kirn disposes of common shares worth $1,068,651.63](https://longbridge.com/en/news/296648682.md)
- [SharkNinja to join Goldman Sachs Global Consumer and Retail Conference fireside chat](https://longbridge.com/en/news/297648781.md)
- [International Frontier Resources, Kinjal sign deals to buy Jaguar’s 57.37% stake in Tonalli unit](https://longbridge.com/en/news/297917027.md)
- [Impinj, Inc. (NASDAQ:PI) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/297998475.md)
- [Republic Services Earns Great Place to Work Certification for 10th Consecutive Year | RSG Stock News](https://longbridge.com/en/news/297548441.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**